Two recent studies have revealed promising developments that could revolutionize early detection methods for Alzheimer's, as it has become possible to detect changes associated with the disease many years before symptoms appear.
Researchers hope that these developments, which include simpler blood tests and more accurate brain imaging techniques, will contribute in the future to diagnosing the disease in its early stages, giving patients better opportunities to benefit from modern treatments and preventive interventions before symptoms worsen.
In the first study, published in The Lancet, researchers found that some biomarkers associated with Alzheimer's disease can be detected in the blood of middle-aged people, even before any obvious signs of dementia or cognitive decline appear.
The study involved analyzing blood samples from 1,350 people in the United States, with an average age of 61, who did not have dementia. Researchers focused on measuring levels of proteins associated with the accumulation of amyloid and tau, two of the most prominent biological markers linked to Alzheimer's disease.
The results showed that 86 participants had high levels of these biomarkers, which was associated with poorer performance on memory and cognitive ability tests, as well as a faster decline in some cognitive skills during a five-year follow-up period.
The researchers believe that these findings reinforce the hypothesis that Alzheimer's disease begins to develop inside the brain decades before its clinical symptoms appear, opening the door to the possibility of early intervention to reduce the progression of the disease or delay the onset of dementia.
The research team pointed out that using blood tests to detect these changes could be an important step in developing future preventive programs, especially since these tests are less expensive and easier to apply compared to traditional diagnostic methods.
In a second study, also published in The Lancet, researchers tested a new brain imaging technique aimed at the early detection of tau protein tangles, a key feature associated with the development of Alzheimer's disease.
The researchers compared the currently used radioactive tracer "Flortaucipir" with a newer material known as "MK6240" in a study involving 682 people in the United States and Canada.
The results revealed that the new material "MK6240" was able to detect accumulations of the "tau" protein in the early stages at a rate more than double that achieved by the traditional material, indicating its ability to improve the accuracy of early detection of the disease.
Dr. Jackie Hanley, head of research funding at Alzheimer's Research UK, said the two studies represent a further step towards developing more effective methods for early detection of the disease.
She added that the ability to detect Alzheimer's-related changes at an early stage could give patients the opportunity to benefit from modern treatments and participate in clinical trials before the condition worsens.
She also pointed out that blood tests may help in the future to facilitate and speed up disease diagnosis, as they are less invasive and easier to apply on a large scale compared to current tests such as brain imaging.
Despite the promising results, the researchers stressed the need for further studies with larger and more diverse numbers of participants before these techniques are widely adopted in everyday medical practice.
